ong-Term Functional Results of Ewing Tumor Treatment
Phase 4
Recruiting
- Conditions
- 10028389Ewing tumorskeletal malignancy
- Registration Number
- NL-OMON36450
- Lead Sponsor
- Academisch Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 65
Inclusion Criteria
This is a cohort study that will include all patients with histologically confirmed Ewing tumor of the
previous CESS 81, CESS 86, EICESS 92 and ongoing EURO-E.W.I.N.G. 99 (expected closing date end of 2008) of the German Society for Pediatric Oncology and Hematology (GPOH). Additionally, all Ewing tumor patients will be included who have been registered as follow-up patients to the Ewing tumor trail center in Münster from 150 participating institutions in Germany and about 30 additional centers in the neighboring countries. (Among them the AMC)
Exclusion Criteria
Patients with any kind of paralysis will be excluded from the functional measurement (<1%) as the daily activity could not objectively be measured with step monitors.
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method